MediWound (NASDAQ:MDWD) Cut to Hold at Zacks Research

Key Points

• MediWound was downgraded from a "strong-buy" to a "hold" rating by Zacks Research, reflecting a shift in analyst sentiment.
• The company reported a loss of ($1.23) earnings per share for its most recent quarter, missing analysts' expectations by ($0.68).
• MediWound has a market capitalization of $188.49 million and a consensus rating of "Moderate Buy" from several analysts, with an average target price of $32.25.

Zacks Research cut shares of MediWound (NASDAQ:MDWD - Free Report) from a strong-buy rating to a hold rating in a research report report published on Tuesday, August 19th,Zacks.com reports.

Several other research firms also recently weighed in on MDWD. Wall Street Zen downgraded MediWound from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. Oppenheimer began coverage on MediWound in a research note on Monday, June 2nd. They set an "outperform" rating and a $34.00 price target on the stock. HC Wainwright set a $31.00 price target on MediWound and gave the company a "buy" rating in a research note on Thursday, May 22nd. Finally, Alliance Global Partners began coverage on MediWound in a research note on Friday, May 2nd. They set a "buy" rating and a $25.00 price target on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.

MediWound Stock Performance

NASDAQ:MDWD traded down $0.50 during mid-day trading on Tuesday, hitting $16.75. 43,655 shares of the company's stock traded hands, compared to its average volume of 72,035. The company has a fifty day moving average of $19.22 and a 200 day moving average of $18.53. MediWound has a twelve month low of $14.14 and a twelve month high of $22.50. The company has a market capitalization of $181.07 million, a P/E ratio of -6.34 and a beta of 0.21.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.68). MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. The business had revenue of $5.71 million for the quarter, compared to analyst estimates of $5.68 million. On average, research analysts expect that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of MediWound

A number of hedge funds have recently modified their holdings of the stock. Yelin Lapidot Holdings Management Ltd. boosted its stake in shares of MediWound by 0.8% in the first quarter. Yelin Lapidot Holdings Management Ltd. now owns 858,000 shares of the biopharmaceutical company's stock worth $13,316,000 after buying an additional 6,639 shares during the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in shares of MediWound by 41.9% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 147,535 shares of the biopharmaceutical company's stock worth $2,858,000 after buying an additional 43,591 shares during the last quarter. Northern Trust Corp boosted its stake in shares of MediWound by 94.6% in the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock worth $2,577,000 after buying an additional 70,367 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of MediWound by 6.7% in the first quarter. ARK Investment Management LLC now owns 106,930 shares of the biopharmaceutical company's stock worth $1,660,000 after buying an additional 6,684 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of MediWound by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 98,710 shares of the biopharmaceutical company's stock worth $1,757,000 after buying an additional 3,408 shares during the last quarter. Hedge funds and other institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.